- Resilience Government Services received $17.5 million from the US Department of Health and Human Services to expand pharmaceutical manufacturing.
- The funding supports the production of key medicine components, addressing supply chain vulnerabilities.
Resilience Government Services, a subsidiary of National Resilience, has secured approximately $17.5 million in funding to bolster domestic manufacturing of essential pharmaceutical components. The funding comes from the US Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response, specifically through its Center for Industrial Base Management and Supply Chain.
This initiative aims to enhance the production of critical medicine ingredients, including key starting materials and active pharmaceutical ingredients (APIs), essential to securing the pharmaceutical supply chain in the United States. The funding is part of a public-private collaboration with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), focused on strengthening the domestic biomanufacturing infrastructure.
Resilience’s CEO, Rahul Singhvi, commented on the development, stating: “Securing this manufacturing programme for Resilience is a good step forward for the US pharmaceutical manufacturing industry to ensure a more resilient and responsive supply chain.”
The project will leverage Resilience’s certified good manufacturing process (cGMP) facilities and its expertise in analytical development and regulatory compliance. A key component of the initiative will involve the use of Aralez Bio’s advanced enzyme technology, aimed at streamlining API production and meeting FDA requirements to establish Resilience as an approved domestic supplier.
Aralez Bio’s CEO, Tina Boville, added: “Aralez Bio’s proprietary enzyme platform is at the forefront of amino acid chemistry. When combined with Resilience’s groundbreaking approach to pharmaceutical manufacturing, this collaboration is strengthening the security of our supply chains.”